5 COVID-19 VACCINES UNDER CLINICAL TRIALS IN INDIA

5 MORE COVID-19 VACCINES UNDER TRIALS IN INDIA 2021

In order to respond quickly and effectively to the COVID-19 pandemic, a broad range of candidate COVID-19 vaccines are being investigated globally using various technologies and platforms. These include viral-vectored, protein subunit, nucleic acid (DNA, RNA), live attenuated and inactivated vaccines. Previously two candidates of the vaccine have been approved for emergency use i.e. Covishield & Covaxin. Some of these candidates have entered under clinical trials.

  1. ZyCov-D
  2. Biological E’s novel Covid-19 vaccine
  3. BBV154 – Intranasal vaccine
  4. COVOVAX
  5. mRNA based vaccine (HGCO19)

ZyCoV-D

Zydus Cadila, ZyCoV-D

Zydus Cadila, focused on discovering and developing NCEs, Novel Biologicals, Biosimilars and Vaccines, announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D. Safety in Phase I clinical trial of ZyCoV-D in healthy subjects established as endorsed by the independent Data Safety Monitoring Board (DSMB). Zydus commenced Phase II trial.

  • DCGI approval for Phase I & Phase II Human Clinical Trials RECEIVED
  •  Phase I Human Clinical Trial COMPLETED
  •  Phase II Human Clinical Trial COMPLETED
  •  Phase III Human Clinical Trial ONGOING
  •  DCGI approval for Phase III Human Clinical

Biological E’s novel Covid-19 vaccine

Biological E’s novel Covid-19 vaccine

Biological E. Limited is conducting a prospective open label randomised Phase-I seamlessly followed by Phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E’s novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule(0, 28D) to healthy volunteers.

  • DCGI approval for Phase I & Phase II Human Clinical Trials RECEIVED
  •  Phase I/II Human Clinical Trial ONGOING

BBV154 – Intranasal vaccine

BBV154 – Intranasal vaccine

Bharat Biotech is conducting Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenoviral vector COVID-19 vaccine (BBV154) in Healthy Volunteers. BBV154 is an intranasal vaccine that stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.  Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19.

  •  DCGI approval for Phase I Human Clinical Trials RECEIVED
  •  Phase I Human Clinical Trial ONGOING.

COVOVAX

COVOVAX

Indian Council of Medical Research and Serum Institute of India jointly performing a phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults.

  •  DCGI approval for Phase 2/3 Human Clinical Trial RECEIVED
  •  Phase 2/3 Human Clinical Trial ONGOING

mRNA based vaccine (HGCO19)

HGCO19

Randomized, Phase I/II, Placebo-controlled, Dose-Ranging, study to evaluate the Safety, Tolerability and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy adult subjects. The trial is being conducted by Gennova Biopharmaceuticals Limited.

  • DCGI approval for Phase I/II Human Clinical Trial RECEIVED
  •  Phase I/II Human Clinical Trial ONGOING.

Bibliography: Indian Council of Medical Research (ICMR) & WHO.

Join Our WhatsApp Group to receive the latest updates like Pharma Job notifications, study materials, admission alerts, Pharma News, etc.

Join Our Telegram Group to receive the latest updates like Pharma Job notifications, study materials, admission alerts, Pharma News, etc

Join Our Telegram Group to Download Free Booksfor D.Pharm, B.Pharm, M.Pharm & GPAT

Subscribe to our newsletter!! Sign up here

By submitting your information, you're giving us permission to email you. You may unsubscribe at any time.!

Leave a Comments here

Message us
1
Need Help?
Hello...
Have you any Inquiry? Please leave a message. Our team will reply ASA
%d bloggers like this: